Wolverine Trading, LLC Arbutus Biopharma Corp Put Options Transaction History

Wolverine Trading, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $64,896 - $94,847	20,800 New	20,800 $80,000
Q1 2023 May 15, 2023	SELL	$2.23 - $3.1 $23,415 - $32,550	-10,500 Reduced 50.24%	10,400 $31,000
Q4 2022 Feb 14, 2023	SELL	$1.91 - $2.85 $12,224 - $18,240	-6,400 Reduced 23.44%	20,900 $49,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $188 - $288	-100 Reduced 0.36%	27,300 $54,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $85,734 - $137,261	-43,300 Reduced 61.24%	27,400 $74,000
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $62,920 - $103,480	26,000 Added 58.17%	70,700 $211,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $139,017 - $206,067	44,700 New	44,700 $173,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $481M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.